Michael Freeman

Stock Analyst at Raymond James

(2.67)
# 2,770
Out of 5,182 analysts
5
Total ratings
80%
Success rate
15.24%
Average return

Stocks Rated by Michael Freeman

Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $6.94
Upside: +101.73%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $28.75
Upside: +164.35%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $18.04
Upside: +105.10%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $68.85
Upside: +29.27%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $5.58
Upside: +43.37%